Genes tied to GLP‑1 response

Your body already has a built-in “meal arrived” signal. After you eat, gut hormones tell the brain to ease hunger, tell the stomach to empty more slowly, and tell the pancreas to help manage blood sugar. (nature.com) Drugs like semaglutide copy one of those gut signals, called glucagon-like peptide 1, and drugs like tirzepatide copy two signals at once, including glucose-dependent insulinotropic polypeptide. That is why they can cut appetite hard enough that some patients lose more than 20% of body weight, while others lose less than 5%. (nature.com, 23andme.com) The tradeoff is often stomach trouble. The United States prescribing information for Wegovy lists nausea and vomiting among common side effects, and Zepbound is labeled as a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist with gastrointestinal warnings as well. (accessdata.fda.gov, accessdata.fda.gov) The mystery has been why two people can take the same shot and get very different results. A genome-wide association study is the genetics version of a giant pattern hunt, where researchers scan DNA across a large group and ask which tiny differences show up more often in people with a specific outcome. (nature.com) In this new study, 23andMe researchers ran that pattern hunt in 27,885 people who reported using these medicines. They compared DNA with two outcomes people care about most: how much weight they lost and whether they got nausea or vomiting. (nature.com, 23andme.com) One signal landed in a gene called GLP1R, which is the instruction manual for the receptor these drugs are built to hit. The paper says a missense variant there, meaning a one-letter DNA swap that changes the protein itself, was linked to an extra 0.76 kilograms of weight loss for each copy of the effect version a person carried. (nature.com, 23andme.com) The side-effect signal was split across two genes. Variation in both GLP1R and GIPR, the gene for the glucose-dependent insulinotropic polypeptide receptor, was associated with nausea or vomiting after treatment. (nature.com) One detail stood out: the GIPR link showed up only in people using tirzepatide, not semaglutide. That fits the biology, because tirzepatide targets the glucose-dependent insulinotropic polypeptide pathway and semaglutide does not. (nature.com, 23andme.com) The researchers then combined these gene signals with demographic and clinical data to sort people by likely benefit and likely side-effect risk. That does not mean a cheek swab can pick the perfect drug today, but it does mean the field is moving toward obesity treatment that works more like matching eyeglasses to a prescription than handing everyone the same pair. (nature.com, 23andme.com) There are still two big catches. The study used self-reported outcomes, and the authors describe this as groundwork for precision medicine rather than a ready-to-use clinic test. (nature.com, 23andme.com) What changed this week is that the variation is no longer just anecdotal. A paper in Nature on April 8, 2026 tied part of the “why did this work for my friend but not for me” question to common DNA differences in the exact receptors these blockbuster drugs are designed to push. (nature.com, statnews.com)